Skip to Content
Søg Menu

ASCO GU 2024: CheckMate 914 Trial – Adjuvant Nivolumab Monotherapy vs Placebo for Localized Renal Cell Carcinoma at High Risk of Relapse After Nephrectomy

This article reviews the outcomes of the CheckMate 914 trial, primarily focusing on Part B, which examined the efficacy of adjuvant Nivolumab (NIVO) monotherapy versus placebo (PBO) in patients with high-risk localized renal cell carcinoma (RCC) post-nephrectomy.

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Relateret indhold

Maria Teresa Bourlon

Nivolumab + Cabozantinib Remains Standard of Care in First-Line Treatment for Advanced Renal Cell Carcinoma

/ Maria Teresa Bourlon
Nyrecancer Play the Video 5:36
Marc Eid og Karl Semaan

Cancer Epigenomics Improve the Overall Survival and the Quality of Life

/ Marc Eid / Karl Semaan
ASCOGU24Prostatacancer Play the Video 1:31
Wadih Issa

Comparing Downstaging in RCC-Patients with Tumor or Without Tumor Thrombus Receiving Neoadjuvant ICI Regimen

/ Wadih Issa
ASCOGU24Nyrecancer Play the Video 1:47
Marc Machaalani

Host Immune Signatures as Predictors for Immunotherapy Regimens in Patients with Metastatic Renal Cell Carcinoma

/ Marc Machaalani
Nyrecancer Play the Video 2:11
Eddy Saad

Understanding Mechanisms Behind Acquired Resistance to Immunotherapy in Metastatic Renal Cell Carcinoma

/ Eddy Saad
ASCOGU24Nyrecancer Play the Video 2:21
Renee Maria Saliby

The Potential for Intermediate Clinical Endpoints as Surrogates for Overall Survival

/ Renee Maria Saliby
ASCOGU24Nyrecancer Play the Video 2:46
Jakob Lauritsen

Highlights fra ASCO GU 2024 om prostatacancer i en dansk kontekst

/ Jakob Lauritsen
ASCOGU24Prostatacancer Play the Video 4:21
Philipp Ivanyi

Real-World Evidence on Lenvatinib plus Everolimus in Patients with Pre-Treated Advanced Renal Cell Carcinoma

/ Philipp Ivanyi
ASCOGU24Nyrecancer Play the Video 3:16
Ahmed Rehan

Real-World Data on Maintenance Avelumab Treatment

/ Ahmed Rehan
ASCOGU24Blærecancer Play the Video 2:14

Brænder du for at skrive?

Vil du gerne dele din forskning eller dine kliniske erfaringer med dine kollegaer inden for netop dit speciale? Har du en ide til en artikel, som du gerne vil udgive hos os? Send redaktionen en mail på redaktion@bpno.dk

Send mail til redaktionen
Back to top